Indaptus Therapeutics, Inc.

corporate_fare Company Profile

Indaptus Therapeutics, Inc.

INDP·NASDAQ·Life Sciences·CIK 0001857044

Indaptus Therapeutics, Inc. is a clinical biotechnology company focused on developing immunotherapy products to combat cancer and viral infections. Its primary product in development is Decoy20. This candidate is designed to be used either alone or in combination with other therapies to achieve lasting responses in various conditions. These include lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infections. Decoy20 is also being developed for the treatment of advanced solid tumors. The company, which was previously known as Intec Parent, Inc., adopted the name Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is based in New York, New York.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for INDP at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

New Investor Group Acquires 98% of Indaptus Therapeutics, Appoints New CEO, Completing Change of Control (2026-03-31)
Indaptus Therapeutics Undergoes Near-Total Ownership Change, Appoints New CEO Amid $11.2M Preferred Stock Sale (2026-03-24)
Co-CEO Sells Controlling Stake for $11.2M, Resigns Amidst Company Distress (2026-03-24)
Director Disposes of Preferred Stock Convertible to 108.9M Common Shares Amidst Going Concern Warning (2026-03-24)
Indaptus Therapeutics Faces Delisting Risk Amidst Clinical Halt and Extreme Dilution from $6M "Rescue" Financing (2026-03-17)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-$20.85M

Diluted EPS

-$21.58

Op. Cash Flow

-$14.82M

Operating Income

-$19.83M

Cash & Equivalents

$8.51M

Debt / Equity

0.00×

Shares Outstanding

2.17M sh

Source: 10-K · filed 2026-03-17 · accession 0001493152-26-010585

show_chartPrice Chart

Loading chart...

feed INDP - Filings & News (Page 2)

Filing Type

Date Range

INDP

Mar 30, 2026, 9:46 PM EDT

Filing Type: SCHEDULE 13D

Importance Score:

New Investor Group Acquires 98% of Indaptus Therapeutics, Appoints New CEO, Completing Change of Control

Price at Filing: $1.78

Real-time Price: $2.38

Change: +$0.600 (+34%)

Market Cap: $365.524M

Sentiment: Neutral

View Wiseek Article

INDP

Mar 24, 2026, 4:30 PM EDT

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Undergoes Near-Total Ownership Change, Appoints New CEO Amid $11.2M Preferred Stock Sale

Price at Filing: $1.68

Real-time Price: $2.38

Change: +$0.700 (+42%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Mar 24, 2026, 4:05 PM EDT

Filing Type: SCHEDULE 13D/A

Importance Score:

Co-CEO Sells Controlling Stake for $11.2M, Resigns Amidst Company Distress

Price at Filing: $1.67

Real-time Price: $2.38

Change: +$0.7099 (+43%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Mar 24, 2026, 4:02 PM EDT

Filing Type: 4

Importance Score:

Director Disposes of Preferred Stock Convertible to 108.9M Common Shares Amidst Going Concern Warning

Price at Filing: $1.70

Real-time Price: $2.38

Change: +$0.680 (+40%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Mar 17, 2026, 4:30 PM EDT

Filing Type: 10-K

Importance Score:

Indaptus Therapeutics Faces Delisting Risk Amidst Clinical Halt and Extreme Dilution from $6M "Rescue" Financing

Price at Filing: $1.96

Real-time Price: $2.38

Change: +$0.420 (+21%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Mar 02, 2026, 5:20 PM EST

Filing Type: SCHEDULE 13D

Importance Score:

Co-CEO David Lazar Discloses 98% Beneficial Ownership Following $6M Preferred Stock Conversion

Price at Filing: $2.10

Real-time Price: $2.38

Change: +$0.280 (+13%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Feb 27, 2026, 4:05 PM EST

Filing Type: 8-K

Importance Score:

Shareholders Approve Massive Dilution, Control Change to David Lazar, and Reverse Stock Split Authority

Price at Filing: $2.06

Real-time Price: $2.38

Change: +$0.317 (+15%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Feb 12, 2026, 9:30 AM EST

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Reprices Over 1.6M Warrants to $1.75, Securing Votes for Critical Financing

Price at Filing: $1.78

Real-time Price: $2.38

Change: +$0.600 (+34%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Feb 12, 2026, 9:30 AM EST

Filing Type: DEFA14A

Importance Score:

Indaptus Therapeutics Reprices Warrants to $1.75 and Secures Votes for Dilutive Financing

Price at Filing: $1.78

Real-time Price: $2.38

Change: +$0.600 (+34%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Jan 21, 2026, 5:21 PM EST

Filing Type: DEF 14A

Importance Score:

Indaptus Seeks Shareholder Approval for Highly Dilutive $6M Financing, Ceding 96.4% Control to New Co-CEO David Lazar

Price at Filing: $2.65

Real-time Price: $2.38

Change: -$0.270 (-10%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Jan 20, 2026, 4:06 PM EST

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Co-CEO and CSO Salaries Cut to $60K Amidst Financial Restructuring

Price at Filing: $2.89

Real-time Price: $2.38

Change: -$0.510 (-18%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Jan 08, 2026, 5:26 PM EST

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Appoints Experienced Independent Director David Natan to Board and Audit Committee

Price at Filing: $3.05

Real-time Price: $2.38

Change: -$0.670 (-22%)

Market Cap: $365.524M

Sentiment: Positive

View Wiseek Article

INDP

Jan 08, 2026, 5:22 PM EST

Filing Type: PRE 14A

Importance Score:

Indaptus Therapeutics Seeks Shareholder Approval for $6M Financing, Leading to 95.6% Control by New Investor and Massive Dilution

Price at Filing: $3.03

Real-time Price: $2.38

Change: -$0.650 (-21%)

Market Cap: $365.524M

Sentiment: Negative

View Wiseek Article

INDP

Jan 02, 2026, 4:07 PM EST

Filing Type: 8-K

Importance Score:

Indaptus Therapeutics Board Sees Three Directors Resign Ahead of Shareholder Meeting

Price at Filing: $2.74

Real-time Price: $2.38

Change: -$0.360 (-13%)

Market Cap: $365.524M

Sentiment: Neutral

View Wiseek Article

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets

corporate_fare Company Profile